March 7, 2025
Tag: Matthew Milowsky
February 21, 2025
CancerNetwork: Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU
February 21, 2025
Medscape: Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis
February 17, 2025
MedPage Today: Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer
February 17, 2025
CURE: Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC
February 14, 2025
CancerNetwork: Adjuvant Nivolumab Shows Sustained DFS Benefit in High-Risk Bladder Cancer
February 14, 2025
OncLive: Updated CheckMate-274 Data Further Support Adjuvant Nivolumab as SOC for High-Risk MIUC
November 14, 2024
ASCO Post: Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care
November 14, 2024
Inside Precision Oncology: Bladder Cancer Biomarkers Promise Improved Survival
November 13, 2024
Treatment advances, predictive biomarkers stand to improve bladder cancer care
In an editorial, Matthew Milowsky, MD, FASCO, wrote that the promise of incorporating new treatments and predictive biomarkers to select the right patient for the right treatment every time offers a bright future for bladder cancer patients.